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Objective: Small aortic valve replacement remains a challenging hemodynamic
problem. A new bioprosthesis (3F Therapeutics, Lake Forest, Calif) was designed to
further improve the hemodynamic performance currently achieved with stentless
bioprostheses. This valve consists of a tubular structure assembled from 3 equal
sections of equine pericardial material, with virtually no foreign material except for
a thin polyester ring. Its hemodynamic performance was compared with that of a
commercially available stentless prosthesis in a bovine model.
Patients and Methods: Twelve calves (55 2.8 kg) received a 19-mm 3F valve (3F
group, n  6) or a 19-mm stentless control valve (control group, n  6). The
animals were fully equipped for hemodynamic monitoring and transvalvular gradi-
ent measurements. After implantation, dopamine was infused in increasing doses,
and the hemodynamic values were recorded at each step of 100-g/min increase.
Linear regression analysis was applied for group comparison of each variable.
Results: The mean transvalvular gradient at 4.5 L/min was 3.48  0.14 mm Hg
(95% confidence interval) in the 3F group and 5.72  0.28 mm Hg in the control
group (P  .0001) and at 6.5 L/min, 7.4  1.55 mm Hg, and 11.13  0.18 mm Hg,
respectively (P .0001). The effective orifice area at 4.5 L/min was 2.4 0.03 cm2
in the 3F group and 1.86  0.02 cm2 in the control group (P  .0001) and at 6.5
L/min, 2.41  0.04 cm2, and 1.96  0.02 cm2, respectively (P  .0001).
Conclusions: This new bioprosthesis without a stent and without a supporting wall
that has its commissures fixed directly to the aorta outperforms in vivo standard
stentless prostheses in the immediate postimplant period.
Although stented bioprostheses avoid the need for anticoagulation,valve stents have 2 main drawbacks. First, stents have been shownto increase stress on the biologic cusp tissue in fatigue-testingmodels.1 This feature has been involved as the source of leafletcalcification, with subsequent limited valve durability. Second,the obstructive nature of rigid stents leads to a nonphysiologic
flow pattern and residual gradient, which would inhibit complete resolution of left
ventricular hypertrophy and lead to lower long-term survival.2
Stentless aortic xenograft valves offer the potential to overcome the problems
associated with stented valves and to mimic the hemodynamic performance of
homografts.3 Despite excellent initial results after its clinical introduction,4,5 pre-
mature structural deterioration because of poor preservation methods hampered its
further application. The introduction of glutaraldehyde by Carpentier and associ-
ates6 in 1968, with the subsequent widespread use of stented bioprostheses in the
early 1980s, renewed the interest in stentless xenograft valves. David and col-
leagues7 began to implant stentless porcine aortic valves in sheep in 1988, with
encouraging hemodynamic results. The 1990s have witnessed the introduction of
innovative stentless aortic valves, among which the United States Food and Drug
Administration approved the Toronto SPV valve (St Jude Medical, Inc, St Paul,
Minn) and the Freestyle valve (Medtronic, Inc, Minneapolis, Minn).
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Nevertheless, any aortic valve substitute, even the stent-
less valve, has its inherent obstructive feature. In both the
Toronto SPV and Freestyle valves, the leaflets are supported
by a Dacron cloth, as well as by the aortic wall of the
xenograft. This support apparatus represents additional ma-
terial within the recipient root. A new bioprosthesis (3F
Therapeutics, Lake Forest, Calif) was designed to further
diminish these obstructive features. This valve consists of a
tubular structure assembled from 3 equal sections of equine
pericardial material with virtually no foreign material ex-
cept for a thin polyester ring. Because residual gradient is a
concern, especially in patients with small aortic roots, this
experimental study was designed to compare the hemody-
namic performance of the 19-mm 3F valve with that of the
Toronto SPV valve of corresponding size in a calf model.
Material and Methods
Study Design
The protocol described herein was reviewed and approved by the
Committee on Animal Care, Office Ve´te´rinaire Cantonal, Lau-
sanne, Switzerland. All animals received care in compliance with
the “Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research, and the “Guide for the
Care and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996.
Valve Design
The 3F valve is a low-pressure glutaraldehyde-fixed pericardial
bioprosthesis that consists of a tubular structure assembled from 3
equal sections of equine pericardial material (Figure 1). The 3
leaflets have been assembled with locking sutures. Three tabs have
been placed at the outflow, simulating commissures that allow
fixation in the vicinity of the sinotubular junction. These tabs are
reinforced with equal sections of polyester material that also will
serve to promote ingrowth of the tab into the aortic wall. Leaflets
and tabs are one integral structure. At the inflow area of the tubular
structure, a slightly scalloped polyester ring has been incorporated
to allow easy suturing of the bioprosthesis to the bottom of the
aortic sinus, thus securing it and minimizing the potential for
perivalvular leakage. It is expected that this ring will help the
promotion of ingrowth of fibrous material to anchor the valve
firmly to the root of the aorta.
The tubular structure design was derived from the primal
tubular structure of human heart valves found during their devel-
opment in utero. When the blood flow through the heart is estab-
lished, this tubular structure adopts the form found when fully
developed. That is to say that “Form Follows Function” (3F).
Figure 2 illustrates this concept.
Animal Preparation
This study was conducted in 12 calves with a mean body weight of
55  2.8 kg (SD). This weight range was chosen because it
corresponds to an aortic annulus size of 19 mm. The animals were
equipped, after achievement of general anesthesia, with a Swan-
Ganz catheter (Edwards Lifesciences, Irvine, Calif) and a femoral
arterial catheter for hemodynamic monitoring. The Swan-Ganz
catheter was inserted through the right jugular vein into the pul-
monary artery to measure pressures of the right-sided heart cham-
bers with continuous cardiac output monitoring (Vigilance Moni-
tor; Baxter, Irvine, Calif). Three electrocardiographic leads were
installed. A median sternotomy was performed. The pericardium
was opened and reflected to form a cradle for suspending the heart.
Two 8F high-fidelity micromanometer-tipped catheters (Millar
Instruments, Inc, Houston, Tex) were inserted into the left ventri-
cle through the apex of the heart and into the ascending aorta
through the left internal thoracic artery, respectively. Simultaneous
recording of the left ventricular pressure and the ascending aortic
pressure was used to measure transvalvular gradient. Heparin (F.
Hoffmann-La Roche & Co, Basle, Switzerland), 300 IU/kg body
weight, was given systemically, and the activated clotting time was
kept at greater than 400 seconds throughout the experiment.
Because of the short length of the ascending aorta, both the
right carotid artery and the aortic arch were cannulated. For the
venous return, a double-stage cannula was introduced into the right
atrium. A standard cardiopulmonary bypass (CPB) circuit was
connected. Whole-body perfusion was then instituted, with the
blood flow rate maintained by a roller pump at 60 to 80 mL · kg1
· min1. Body temperature was lowered to 28°C. After the bra-
chiocephalic trunk and the ascending arch had been crossclamped
with a single clamp, 1 L of cold crystalloid solution was injected
through a cardioplegia needle at the base of the aorta. The distal
ascending aorta was transected to expose the aortic valve and to
allow maximal length of the aortic root for proper implantation of
the valve. The transection provides better exposure than when the
aorta is not completely transected, and it preserves the normal
anatomic structure of the root. The native aortic cusps were then
carefully excised.
The 12 animals were randomly assigned to either a 3F valve
(3F group) or a Toronto SPV valve (control group). Before im-
plantation, the aortic annulus size was assessed with a 19-mm
Figure 1. 3F aortic pericardial bioprosthesis.
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Hegar dilator. When a 3F valve was inserted, its polyester ring was
secured to the annulus with 2-0 Ti-Cron (United States Surgical
Corp, Norwalk, Conn) interrupted sutures. Then each tab was fixed
to the aortic wall with a transmural 4-0 Prolene (Ethicon, Inc,
Somerville, NJ) U stitch.
When a Toronto SPV valve was used, its annulus was secured
in a similar fashion. The valve was oriented such that the largest
opening faced the left ostium. After tying the proximal suture line,
the commissural posts were held in place with stay sutures of 4-0
Prolene to achieve proper orientation. Then the distal suture line
was performed with a running 4-0 Prolene suture.
After valve implantation, the aorta was partially closed with a
running 4-0 Prolene suture. Once the deairing maneuver was
performed, the aortotomy was sealed and the crossclamp was
removed. After rewarming, the heart was defibrillated if necessary.
When normal sinus rhythm was established, the animal was care-
fully weaned from CPB with a dopamine support of 200 g/min,
and volume was adjusted as needed.
Hemodynamic Recording
After weaning from CPB, a period of 20 minutes of stabilization
was allowed before recording the cardiac output, the mean trans-
valvular gradient, and the maximal transvalvular gradient. Data
were recorded digitally online with a sampling rate of 250 Hz per
channel (Transceiver unit TRx 001; Sonometrics, London, On-
tario, Canada). Mathematic analysis of the data was performed
offline with a software package for cardiovascular analysis
(Sonosoft version 3.1.3., Sonometrics). The hemodynamic data
were obtained by measuring 5 consecutive beats twice at 1-minute
intervals. Then the dose of dopamine was increased at 20-minute
intervals by using 100 g/min. At the end of each period, the
hemodynamic data were recorded. The procedure was stopped
when the heart rate exceeded 120 beats/min.
Calculations
Valve orifice area (VOA) in square centimeters was calculated by
the formula of Gorlin and Gorlin8:
VOA CO/44.3 (SEP) (HR)MPG
where CO is the cardiac output (in liters per minute), SEP is the
systolic ejection period (in milliseconds), HR is the heart rate (in
beats per minute), and MPG is the mean pressure gradient (in
milliliters of mercury).
The valve resistance (VR; dyne · cm · s5) was calculated
according to the following formula9:
VR 1.33 (MPG) (HR) (SEP) /CO.
Statistics
Values are given as means  SD. Correlations between hemody-
namic parameters (mean transvalvular gradient, maximal transval-
vular gradient, valve orifice area, and valve resistance) and cardiac
output were performed with linear regression analysis, according
to the least-squares method. Then each hemodynamic parameter,
as determined by means of regression analysis, was further exam-
ined with the unpaired Student t test between the 2 valve groups.
Results
The 3F aortic valve could be implanted in all the animals,
with successful weaning from CPB and complete hemody-
namic measurements obtained. Sinus rhythm was main-
tained during the complete set of measurements. Four steps
of measurements could be performed in each animal, except
for one animal in the standard group, in which 5 steps could
be performed. Therefore, for each parameter, 240 measure-
ments were available in the 3F group and 250 measurements
in the standard group.
The mean heart rate was 89.7  11.9 beats/min during
the first series of measurements and 116.4  3 beats/min
during the last series. Aortic crossclamp time was 74  7
minutes for the 3F group and 92 5 minutes for the control
group (P  .0001).
Linear regression analysis of the mean transvalvular gra-
dient according to the cardiac output is shown on Figure 3.
The difference between both groups is statistically signifi-
cant (P  .0001), with gradients of 3.48  0.14 mm Hg
(95% confidence interval [CI]) for the 3F group versus 5.72
 0.28 mm Hg for the standard group at 4.5 L/min and
gradients of 7.4 1.55 mm Hg versus 11.13 0.18 mm Hg
at 6.5 L/min, respectively.
Figure 4 shows the linear regression analysis of the
maximal transvalvular gradient according to the cardiac
output. The difference between both groups was statistically
significant (P  .0001), with gradients of 30.75  0.55 mm
Hg (95% CI) for the 3F group versus 43.88  0.9 mm Hg
Figure 2. A, Primal tubular structure of human heart valve during
development in utero. B, The white dots indicate the points of
fixation of the tubular structure (ie, the commissural areas). When
fluid flows through this tubular structure, the points of fixation
will automatically determine the form of the valve.
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for the standard group at 4.5 L/min and gradients of 47.73
 0.59 mm Hg versus 73.5  0.8 mm Hg at 6.5 L/min,
respectively.
Linear regression analysis of the valve orifice area ac-
cording to the cardiac output is shown in Figure 5. The
difference between both groups was statistically significant
(P .0001), with values of 2.4 0.03 cm2 (95% CI) for the
3F group versus 1.86  0.02 cm2 for the standard group at
4.5 L/min and values of 2.41 0.04 cm2 versus 1.96 0.02
cm2 at 6.5 L/min, respectively.
Figure 6 describes the linear regression analysis of the
valve resistance according to the cardiac output. The differ-
ence between both groups was statistically significant (P 
.0001), with values of 23.76  0.76 dyne · cm · s5 (95%
CI) for the 3F group versus 39.05 0.99 dyne · cm · s5 for
the standard group at 4.5 L/min and values of 34.15  0.81
dyne · cm · s5 versus 51.12  0.87 dyne · cm · s5,
respectively, at 6.5 L/min.
Detailed figures of the regression analysis are shown in
Table 1.
Discussion
This in vivo hemodynamic study comparing the 19-mm 3F
valve with the 19-mm Toronto SPV valve shows a clear
advantage for the 3F valve both in term of implantation time
and hemodynamic profile. All the hemodynamic parameters
studied were improved over the whole range of cardiac
output tested. As expected, transvalvular gradients and
valve resistance increased with cardiac output in both
groups. Interestingly, valve orifice area increased with car-
diac output in the Toronto SPV group, whereas it remained
stable in the 3F group, with clearly superior values even at
the higher end of the cardiac output spectrum.
The principle of the 3F valve reverses the usual concept
of imitating the final form of a defined structure. On the
contrary, the 3F design is derived from the primal tubular
structure of human heart valves found during their original
development. The 3 points of fixation of this tubular struc-
ture will determine the subsequent form of the valve once
blood flow is established (ie, once its function is acquired).
This concept allows for a dramatic simplification of the
Figure 5. Valve orifice area (VOA): regression analysis according
to the cardiac output (CO). Dotted lines, 95% CI.
Figure 6. Valve resistance (VR): regression analysis according to
the cardiac output (CO). Dotted lines, 95% CI.
Figure 3. Mean transvalvular gradient: regression analysis ac-
cording to the cardiac output (CO). Dotted lines, 95% CI.
Figure 4. Maximal transvalvular gradient: regression analysis
according to the cardiac output (CO). Dotted lines, 95% CI.
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prosthetic structure. When compared with the Toronto SPV
valve and the Freestyle valve, 3 features have been funda-
mentally modified: the absence of a supporting xenograft
aortic wall, the reduction of synthetic cloth, and the absence
of a muscle bar.
First, there is no supporting wall. This might reduce
transprosthetic gradients in 2 ways. On the one hand, the
xenograft aortic wall itself is an obstructive element once
implanted within the native aortic root. On the other hand,
analysis of hemodynamics and left ventricular mass regres-
sion after implantation of the Toronto SPV valve,10-12 as
well as the Freestyle valve,13-15 have shown repeatedly a
significant decrease in transvalvular gradient over the first
year after implantation. Although ventricular remodeling
has been involved as the major contributor to this decrease
beyond the first 3 to 6 postoperative months, absorption of
the hematoma in the potential space between the porcine
and the native aortic walls appears more likely to be the
predominant mechanism in the early postoperative period.
The absence of any supporting structure offers to the 3F
valve the potential for optimal gradient as soon as the
implantation time. This hypothesis is supported by the anal-
ysis of gradient profile over the time of the Freestyle valve
implanted as a root replacement.16 In contrast to the sub-
coronary implant technique and the inclusion technique,
early and late gradients were both low and did not change
with time.
Second, the absence of foreign material except for a thin
polyester ring contrasts with the heavy external Dacron
support found especially in the Toronto SPV valve. This
avoids any unnecessary increase in thickness of the xeno-
graft. Therefore, artificially induced stiffness or stress on the
tissue can be reduced. In keeping with this concept, the
reduction of synthetic supporting structure allows for the
reduction of suture lines.
Third, the pericardial structure of the 3F valve avoids the
presence of the unfavorable muscle bar characteristic of the
base of the porcine right coronary leaflet, therefore maxi-
mizing the valve orifice area. Moreover, coronary ostial
position relative to the annulus might further exaggerate the
problem of the muscle bar. Westaby and coworkers13 have
described the potential pitfall of Freestyle valve linked with
the Dacron structure, particularly over the muscle bar area,
thus generating increased transvalvular gradients.
One of the primary aims of eliminating stents from
bioprosthetic valves was to use the sinus of Valsalva of the
native or xenograft aortic root as a functional stent. This
would allow the leaflets to open more fully as commissures
are pulled apart during systole. Despite the absence of rigid
stents, all currently available stentless valves have some
xenograft or synthetic supporting structure, which might be
viewed as soft stents. The 3F valve explores the stentless
concept further by eliminating supporting components of
any kind.
A substantial advantage of 3F valve implantation lies in
its shorter time of implantation. Instead of 2 suture lines, the
technique involves only one inflow suture line and 3 com-
missural stitches, allowing for reduced crossclamp time.
Moreover, the pliability of the valve facilitates its manipu-
lation, which might be particularly relevant in a small aortic
root. The stability of the 3F valve orifice area at all cardiac
output values tested might be related to its simplified and
pliable structure, contrasting with the greater inertia of the
Toronto SPV valve, especially at low flow rates.
Several features of the study deserve comment. A calf
model has several advantages over other animal models for
acute hemodynamic study of aortic prosthetic valves. A pig
model is limited by post-CPB complications, sheep have a
narrow and fragile aortic root, and goats have limited avail-
ability.
An in vivo rather than in vitro study was performed
because in vitro values have been shown to be unable to
predict the behavior of stentless prostheses in vivo.17 Valve
orifice areas were found to be lower in vivo because stent-
less valves somewhat collapse when inserted in vivo,
whereas in vitro the prostheses are fully expanded and
behave more like stented prostheses.
The 19-mm size was chosen for 2 reasons. On the one
hand, the performance of a valve is better challenged with










3F Control 3F Control 3F Control 3F Control
Slope 1.97 0.05 2.73 0.07 8.55 0.22 14.93 0.32 0.001 0.01 0.05 0.01 5.23 0.3 6.08 0.34
95% CI 1.86 to 2.09 2.58 to 2.87 8.12 to 8.99 14.3 to 15.56 0.02 to
0.02
0.03 to 0.06 4.64 to 5.8 5.4 to 6.76
Deviation from
0 (P)
.0001 .0001 .0001 .0001 .93 .0001 .0001 .0001
Y intercept 5.43 0.31 6.57 0.41 7.77 1.22 23.35 1.82 2.39 0.07 1.62 0.04 0.19 1.66 11.65 1.98
95% CI 6.05 to 4.8 7.39 to 5.76 10.17 to 5.38 26.92 to 19.78 2.25 to 2.54 1.53 to 1.71 3.06 to 3.46 7.77 to 15.53
R2 0.83 0.85 0.86 0.89 0.0001 0.14 0.55 0.54
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is an increasing problem with the aged population. In a
multicenter study, Hvass and associates18 found 171 (30%)
of 561 patients with a small aortic root as defined by a 19-
to 21-mm aortic annulus. In patients older than 80 years of
age, the percentage reached 40%.
A protocol testing hemodynamics over a wide range of
cardiac output allows a better evaluation of valve perfor-
mance when compared with most clinical studies perform-
ing echocardiographic evaluation at rest only. Moreover,
most of these echocardiographic studies do not mention the
cardiac output value at the time of the examination.10,11,13-15
This lack makes any comparison difficult because mean
transvalvular gradient, maximal transvalvular gradient, and
valve orifice area have all been demonstrated to be flow
dependent.19-21
A comparative study was designed because absolute
values found in the experimental setting cannot be extrap-
olated directly to human subjects, mainly because of ana-
tomic differences. For instance, in this study maximal trans-
valvular gradients have been found to be disproportionately
high in comparison with mean transvalvular gradients. This
is likely because of the particularly thickened aortic wall of
the calf, which offers a low compliant outflow chamber to
transvalvular blood flow.
As for limitations, this acute experimental model does
not evaluate the long-term outcome of prosthetic valves,
namely degeneration and durability. The theoretical reduc-
tion in leaflet stress leading to improved durability remains
a challenging issue that needs further evaluation. Second,
the sinotubular junction size in human subjects might be
larger than that of the annulus. In the Toronto valve expe-
rience, David22 recommended that the prosthesis should be
sized at the sinotubular junction. This usually leads to an
oversizing of the prosthesis when referred to the annulus.
The problem of 3F valve sizing deserves further evaluation.
Finally, candidates for aortic valve replacement might ex-
hibit a dilative tendency at the level of the sinotubular
junction, which might develop over time. This issue has
been shown to have relevant consequences in terms of late
prosthetic regurgitation.23 Whether the recommendation of
banding the sinotubular junction at the time of Toronto SPV
valve implantation should be applied to the 3F valve needs
to be evaluated.
We thank Philippe Frascarolo, PhD, for his help in the statis-
tical evaluation of this article.
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Discussion
Dr Henry M. Spotnitz (New York, NY). There are other issues
about valve design that you did not address in your presentation.
Can you tell us how the pericardium was preserved if at all,
whether you have any information about long-term durability,
issues of valvular regurgitation, and how critical you consider the
fixation of those tags to the aortic wall? Is that a critical issue, or
can they be sewn anyplace? Does it affect the amount of regurgi-
tation? What else can you tell us about that?
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